Prevalence of switching from two anti-tnf biosimilars back to biologic reference products in Germany
Case Study
Jan 09, 2020

Biosimilars are becoming more and more important for the treatment of many diseases. However, it is not understood how they are tolerated.

Our aim was to analyze the behavior of switching from two anti-TNF biosimilars back to biologic reference products in German patients.